Oesophageal Cancer Trial, Recruiting NCT04455282 Sponsor: Heinrich-Heine University, Duesseldorf Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT04455282
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of cancer (adenocarcinoma) located at the junction where the food pipe meets the stomach (classified as type I or II), confirmed by a tissue sample analysis
  • People aged 18 or older
  • People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by standard medical scoring tools (confirm with trial site for specific score thresholds)
  • People whose cancer has not spread to other parts of the body and is considered removable by surgery, at a stage that meets specific criteria based on how far the cancer has grown and whether nearby lymph nodes are affected (confirm with trial site for exact staging details)
  • People who are able to understand what the study involves and are willing to follow the study procedures, confirmed by signing a consent form

Who may not be able to join:

  • People whose cancer is a different type, such as squamous cell carcinoma, adenosquamous carcinoma, or any other non-adenocarcinoma type
  • People whose cancer has spread to other parts of the body (metastatic), or whose cancer cannot be removed by surgery
  • People whose cancer is at a very early stage with no lymph node involvement (cT1N0), or at a very advanced local stage (cT4b), or whose cancer at stage cT4a has been assessed by the surgical team as not removable with the aim of curing the disease
  • People who have not signed the required consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nikolas Stoecklein, MD, Surgery, University Hospital Düsseldorf Germany

Phone: 004921181

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Heinrich-Heine University, Duesseldorf
Registry
ClinicalTrials.gov
Start date
1 February 2021
Est. completion
30 December 2024

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Difference in CTC detection rate between peripheral and tumor draining veins.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov